Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $53.22 Consensus PT from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $53.2222.

A number of analysts have recently issued reports on the company. Citigroup assumed coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They set an “outperform” rating on the stock. Citizens Jmp restated a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. JonesTrading boosted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Stifel Nicolaus boosted their price objective on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, May 18th. Finally, Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th.

Sionna Therapeutics Trading Up 5.9%

SION opened at $36.05 on Friday. The stock has a market cap of $1.63 billion, a PE ratio of -18.68 and a beta of 1.30. Sionna Therapeutics has a 1 year low of $13.51 and a 1 year high of $48.44. The stock’s 50 day simple moving average is $40.20 and its 200-day simple moving average is $39.73.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Equities analysts forecast that Sionna Therapeutics will post -2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares in the company, valued at $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,717,962 shares of company stock worth $77,571,889 over the last quarter. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics in the fourth quarter worth $36,000. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the third quarter worth $30,000. Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics in the fourth quarter worth $58,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics in the second quarter worth $31,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Sionna Therapeutics in the fourth quarter worth $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.